A new smallpox vaccine was funded by Fauci and the National Institutes of Health in the early 2000s

  1. Donation Campaign June 2022

    Dear reader friends. We are launching a new fundraising campaign for the current month of June, and we are counting on you to help us continue our media work. As you know, there is a cost to maintain and operate our site, and we depend almost entirely on your donation to fund it. Réseau International needs you more than ever to ensure the continuity of its work of thinking and returning information

    Total Donations 5,465.00 euros

by nexus.

More than $100 million is the amount invested since 2001 by Fauci and the National Institutes of Health with the North Bavarian Laboratory to develop a new smallpox vaccine, which will become Imvamune (also called Imvanex or Jynneos), one of today’s recommended monkeypox vaccines.

An article in the Wall Street Journal dated December 2005 sheds light on the strategy for developing new vaccines against smallpox.

Who is Fauci?

Anthony Stephen Fauci is an American immunologist, now 80 years old. Within the National Institutes of Health (NIH), he has since 1984 been director of the National Institute of Allergy and Infectious Diseases (NIAID), a research center of the US Department of Health. He was consecutively the chief public health adviser to eight US presidents, from Ronald Reagan to Joe Biden. At the start of the Covid-19 crisis, he was assigned January 29, 2020 to the Trump Administration’s Coronavirus Crisis Unit (White House Coronavirus Task Force).

At the center of several controversies, Mr. Fauci has co-funded the Wuhan Institute of Virology’s laboratory for coronavirus research and job gains for a total of $7.4 million, according to Newsweek.

Scientist says he wants to fight bioterrorism

In 2005, a Wall Street Journal article explained that in the aftermath of 9/11, Dr. Fauci played “an unusual role for an NIH official in supporting start-ups with NIH grants and contracts” because, he said, market forces were not sufficient “to provide The drugs Americans need to protect themselves from bioterrorism.” Fauci and his agency, whose official name is the National Institute of Allergy and Infectious Diseases, have given “highest priority to Class A pathogens such as anthrax, smallpox and plague.”

The Wall Street Journal reported that funding for the agency for biodefense rose from $42 million annually in 2001 to nearly $1.2 billion in 2003 and nearly $1.7 billion in 2004.

Dr. Fauci says he then decided to “fund big companies”.

Smallpox vaccine: activating competition

In 2001, Bavarian Nordic A/S, a Danish biotechnology company, presented an idea for a smallpox vaccine to the Dr. Fauci Institute. Since the current vaccine was considered too dangerous for vulnerable people, this caught his attention, as it was possible “the new vaccine could be used on patients with AIDS or other diseases that threaten their immune system.”

Dr. Fauci began funding research and development of a new smallpox vaccine in Bavaria, and also began funding a rival company, Acambis PLC. The National Institutes of Health awarded more than $100 million to each company, putting them in the competition.

Bavarian Nordic won the Imvamune or Imvanex vaccine, one of the products offered today against monkeypox. According to La Tribune, in 2007 the United States signed a contract worth $1.18 billion with the Bavarian company Nordic, allied to GlaxoSmithKline (GSK). After the Danish biotech has passed all the stages (development, clinical trials, marketing authorization), the United States ordered 20 million doses.

But a year later, Acambis could not be outdone because, according to L’Usine nouvelle, it announced the signing of a ten-year, multi-million contract with the US government for the ACAM2000 vaccine, now licensed in the US.

Soon again a waltz for vaccines?

While only a few hundred cases have been detected worldwide and most of those infected recover spontaneously within two to four weeks, without specific treatment according to the BFM, the authorities and the media are panicking.

They have already announced the start of vaccination, saying like The Conversation that “although there is no specific vaccine against monkeypox virus, thanks to the so-called cross-protection, smallpox vaccines also work against monkeypox.”

Where are we in the United States?

Today, two smallpox vaccines are licensed in the United States. First of all, ACAM2000, a live attenuated vaccine, not recommended for immunocompromised people and pregnant and breastfeeding women, was approved in 2007 by the Food and Drug Administration, even if it was a repeat. “Although ACAM2000 cannot cause smallpox, the virus it contains can replicate after the vaccine is given and be transmitted from a vaccinated person to an unvaccinated person who comes into contact with the injection site or any fluid flowing from it, for up to 21 days afterward. »

Because of the “significant” potential side effects, their widespread distribution requires “real discussion,” said Jennifer McQuiston, head of the US Centers for Disease Prevention and Control (CDC). The country will have 100,000 doses.

The second licensed vaccine is Genus (also known as Imvamune or Imvanex), a live but non-repetitive vaccine and therefore considered safer, authorized in the United States since September 24, 2019. The United States has only 1,000 doses, according to Low Point.

Where are we in Europe and France?

So far, in Europe, the so-called “third generation” vaccine Imvanex or Imvamune is presented as being the most effective against monkeypox at 85% and causing the fewest side effects. Imvanex has been licensed since 2013 in Europe and received marketing authorization “in exceptional circumstances”, because the European Medicines Agency recognizes that “it was not possible to obtain complete information on Imvanex due to the rareness of the disease”. You undertake to check any new information available each year and update this document if necessary.

Jynneos has not yet received authorization from the European Medicines Agency, but has been introduced as another name for Imvanex in the US by Vaccins.net, because they are identical except for some nuances (residual effects of ciprofloxacin only in the case of Imvanex, shorter use period for Jynneos after dissolution, and obtaining official marketing authorization for the prevention of monkeypox as well as smallpox for Jynneos), however it has been licensed in France for a few days: according to a decree of May 25 2022, “as an exception, it may be authorized in the prophylaxis against monkeypox for persons who are In contact with an infected person or health professionals in care settings exposed to monkeypox virus” Imvanex and Jynneos vaccines, both validated on a waiver basis, both contain a modified form of smallpox virus and are both produced by North Bavaria, laboratory funded by by Dr. Fauci and the National Institutes of Health.

Legeneraliste.fr specifies that they are two live vaccines of the same “highly attenuated” viral strain – “Modern Vaccine Virus from Ankara from Bavaria Nordic (MVA-BN), because they contain the same excipients (trometamol, sodium chloride, water for injection) and about the same” effects Residual” potential (chicken embryo cells, benzonase, gentamicin – and cipro-oxacin only in the case of Imvanex)

Note the difference regarding storage of smallpox vaccines: After thawing, Jynneos should be used more quickly than Imvanex (within 12 hours for Jynneos, within 8 weeks for Imvanex, if stored away from light at 2°C and 8°C).

Besides this distinction in the preservation of vaccines, the main difference between Imvanex and Jynneos appears to be regulatory. “The Imvanex vaccine received European Marketing Authorization (MA) under exceptional circumstances on July 31, 2013 to indicate effective immunization against smallpox in adults,” ANSM reports. The Jynneos vaccine, for its part, “has received marketing authorization in the United States since September 24, 2019 for the prevention of smallpox and monkeypox.” So much so that HAS appears to consider Jynneos to be simply an alternate name for Imvanex, under which the vaccine has received a transatlantic license.

Will it soon be discovered, just as they did with the coronavirus, that they funded research into monkeypox job gains?

Source: Nexus

#smallpox #vaccine #funded #Fauci #National #Institutes #Health #early #2000s

Leave a Comment

Your email address will not be published.